

TECHNICAL BRIEF - JULY 2020

PACKAGE OF CARE FOR CHILDREN AND ADOLESCENTS WITH ADVANCED HIV DISEASE: **STOP AIDS**









TECHNICAL BRIEF — JULY 2020

PACKAGE OF CARE FOR CHILDREN AND ADOLESCENTS WITH ADVANCED HIV DISEASE: **STOP AIDS**

Package of care for children and adolescents with advanced HIV disease: stop AIDS. Technical brief

ISBN 978-92-4-000804-5 (electronic version) ISBN 978-92-4-000805-2 (print version)

© World Health Organization 2020

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. (http://www.wipo.int/amc/en/mediation/rules/)

Suggested citation. Package of care for children and adolescents with advanced HIV disease: stop AIDS. Technical brief. Geneva: World Health Organization; 2020. Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at http://apps.who.int/iris.

Sales, rights and licensing. To purchase WHO publications, see http://apps.who.int/bookorders. To submit requests for commercial use and queries on rights and licensing, see http://www.who.int/about/licensing.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Layout by L'IV Com Sàrl

CONTENTS

ABBREVIATIONS
acknowledgements
BACKGROUND
Current WHO guidelines on managing advanced HIV disease
Tuberculosis Supprococcal disease Supprococcal dise
Tuberculosis. 8 Severe pneumonia 8 Severe bacterial infections 8 Cryptococcal meningitis 9 Malnutrition.
DPTIMIZE
PREVENT
MPLEMENTATION CONSIDERATIONS17National level17Facility level17Health-care providers18Laboratory18Monitoring and evaluation18
RESEARCH GAPS. 20 Clinical research 20 Operational research 20
DEEEDENICES 2

ABBREVIATIONS

BCG Bacille Calmette-Guérin

DTG dolutegravir

EFV efavirenz

E ethambutol

H isoniazid

HPV human papillomavirus

LF-LAM lateral flow urine lipoarabinomannan

LPV/r lopinavir/ritonavir

R rifampicin

TB tuberculosis

Z pyrazinamide

ACKNOWLEDGEMENTS

The Global HIV, Hepatitis and STIs Programme of WHO gratefully acknowledges the contributions of many individuals and organizations to developing this policy brief.

Lisa Frigati led the development of the brief with the contribution of several partners and experts: Nandita Sugandhi (ICAP, Columbia University); Eleanor Magongo (Ministry of Health, Uganda), Yusuf Bhamu, Martina Casenghi, Jennifer Cohn, Judith Kose, Barry Longwe, Lynne Mofenson, Regina Nakiranda and Maryanne Ombija (Elizabeth Glaser Pediatric AIDS Foundation); Ikechukwu Amamilo, Jason Brophy, Naoko Doi, Herb Harwell and Brian Ngwatu (Clinton Health Access Initiative); Esther Casas (Medécins Sans Frontières); Saeed Ahmed (Baylor College of Medicine Children's Foundation Malawi); Janice Lee and Isabela Ribiero (Drugs for Neglected Diseases Initiative); Anna Turkova (University College London); Carmen Perez (Unitaid); Pablo Rojo (Complutense University Madrid); Diana Clarke (Boston University Medical); Angela Colbers (Radboud University, Nijmegen, Netherlands); Brookie Best (University of California, San Diego); Hilary Wolf (United States Centers for Disease Control and Prevention); and Rachel Golin (United States Agency for International Development).

WHO staff: Martina Penazzato, Wole Ameyan, Nathan Ford, Satvinder Singh and Lara Vojnov (Global HIV, Hepatitis and STIs Programme); Annabel Baddeley, Annemieke Brands and Sabine Verkuijl (Global TB Programme).



https://www.yunbaogao.cn/report/index/report?reportId=5_24507

